Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Chickenpox Vaccine Market Growth in 2025?

In the past few years, the market size for the chickenpox vaccine has experienced robust growth. It is set to increase from $3.57 billion in 2024 to $3.8 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.6%. Factors contributing to this growth during the historic period include the progress in vaccine development, regulatory clearances, disease prevalence, vaccination strategies, and public health campaigns.

What Is the Forecast for the Chickenpox Vaccine Market Size Through 2029?

In the forthcoming years, the market size of the chickenpox vaccine is anticipated to witness robust growth, escalating to a value of $4.93 billion in 2029 with a compound annual growth rate (CAGR) of 6.7%. The development during the projected period can be associated with constructive public opinion and confidence, readiness for pandemics, ongoing research and development, increasing demand in emerging markets, and the advancement of healthcare infrastructure. Noteworthy trends during this period will feature educational drives for vaccines, monitoring of adverse events, innovative strategies for vaccine pricing, cutting-edge innovation, and the utilization of AI.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8581&type=smp

What are the Key Market Players in Chickenpox Vaccine Market and How They’re Evolving?

Major companies operating in the chickenpox vaccine market include Merck & Co., Sanofi Pasteur, Takeda Pharmaceutical Company Limited, CSL Limited, Pfizer Inc., Seqirus, Serum Institute of India Pvt. Ltd., Bharat Biotech, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Shenzhen Kangtai Biological Products Co., Ltd., Chongqing Zhifei Biological Products Co., Ltd., Beijing Minhai Biotechnology Co., Ltd., Adimmune Corporation, Biological E. Limited, Walvax Biotechnology Co., Ltd., Zydus Cadila, Indian Immunologicals Ltd., Panacea Biotec Ltd., Bio Farma, PT Kalbe Farma Tbk, CanSino Biologics

What Are the Primary Growth Drivers in the Chickenpox Vaccine Market?

The escalating incidence of chickenpox is anticipated to boost the development of the chickenpox vaccine market. Chickenpox is a severe infectious disease characterized by a fluid-filled, itchy rash, caused by the varicella-zoster virus (VZV). The growing occurrence of chickenpox calls for increased varicella vaccine immunization, thereby intensifying the demand for chickenpox vaccines. For example, a study on GP consultations for chickenpox between September 2016 and December 2022 presented by the National Library of Medicine (NLM), a US-based biomedical library, in October 2023 found an average weekly rate of 3.4 per 100,000 people in England. Typically there’s a surge between weeks 13 and 15 each year, but there was an absence of this pattern during the COVID-19 pandemic, presumably due to social distancing and lockdown measures. Nonetheless, in 2022, consultations rates were more prevalent among children under one year old compared to before the pandemic, indicating fluctuating transmission patterns. Consequently, the upswing in chickenpox disease incidence is fuelling the progress of the chickenpox vaccine market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8581&type=smp

What Are the Leading Segments in the Global Chickenpox Vaccine Industry?

The chickenpox vaccine market covered in this report is segmented –

1) By Vaccine: Monovalent Varicella Vaccine, Combination Varicella Vaccine

2) By Application: Mumps, Measles, Rubella, And Varicella Immunization, Herpes Zoster Immunization, Chickenpox Vaccination

3) By End-Users: Hospitals, Clinics, Other End-Users

Subsegments:

1) By Monovalent Varicella Vaccine: Live Attenuated Varicella Vaccine

2) By Combination Varicella Vaccine: Measles, Mumps, Rubella, And Varicella (MMRV) Vaccine

What Are the Key Market Trends in the Chickenpox Vaccine Industry?

Emerging trends in the chickenpox vaccine market are largely centered around innovative drug developments. Key players in the industry are creating cutting-edge drugs that feature enhanced efficacy and unique derivatives, all designed to solidify their standing in the market. For instance, Sinovac Biotech Ltd., a biopharmaceutical company based in China specializing in vaccine research, development, and production, reported in November 2022 that its live attenuated chickenpox (varicella) vaccine achieved prequalification status from the World Health Organization (WHO), a first-of-its-kind achievement. The vaccine, obtained from the Oka strain, is produced in SINOVAC’s unique Human Diploid Cell (SV-1 strain) by a process involving the cultivation and harvesting of the virus, the addition of stabilizers, and then freeze-drying. The results of a phase III efficacy trial determined that the seroconversion rate of the children who received the vaccine, ranging from 1 to 12 years of age, was at 97.1%. Furthermore, the vaccine displayed an efficacy of 87.1% against varicella and 89.2% against breakthrough varicella. The vaccine also demonstrated complete protection against both mild and severe cases.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/chickenpox-vaccine-global-market-report

What Is the Regional Outlook for the Chickenpox Vaccine Market?

North America was the largest region in the chickenpox vaccine market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chickenpox vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8581

This Report Delivers Insight On:

1. How big is the chickenpox vaccine market, and how is it changing globally?

2. Who are the major companies in the chickenpox vaccine market, and how are they performing?

3. What are the key opportunities and risks in the chickenpox vaccine market right now?

4. Which products or customer segments are growing the most in the chickenpox vaccine market?

5. What factors are helping or slowing down the growth of the chickenpox vaccine market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model